Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody–associated Vasculitis in Canada, 2010–2020

Rituximab (RTX) is the only biologic approved to date for the treatment of antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). 1,2,3 The Canadian Vasculitis Research Network (CanVasc) has recommended RTX as first-line therapy for remission induction, 4 and recently, as the preferred maintenance agent in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). 5